1. Setnikar I, Cereda R, Pacini MA, Revel L (1991) Antireactive properties of glucosamine sulfate. Arzneimittelforschung 41(2):157–161
2. Reginster JY, Bruyere O, Fraikin G, Henrotin Y (2005) Current concepts in the therapeutic management of osteoarthritis with glucosamine. Bull Hosp Jt Dis 63(1–2):31–36
3. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, Herrero-Beaumont G (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil 11(4):290–298
4. Alvarez-Soria MA, Largo R, Calvo E, Herrero-Beaumont G (2005) Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblasts in culture. Osteoarthr Cartil 13:S153
5. Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, Verhaar JA, Weinans H, van Osch GJ (2006) Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthr Cartil 14(3):250–257. doi: 10.1016/j.joca.2005.10.001